Shui, LS, Westcott, PMK (May 2025) Personalized syringes offer hope for pancreatic cancer patients. Immunity, 58 (5). pp. 1182-1184. ISSN 1074-7613
Abstract
Pancreatic cancer has traditionally been considered refractory to immunotherapy. In a follow-up to the first clinical trial of personalized mRNA vaccines against this deadly cancer, published in Nature, Sethna et al. report compelling evidence of long-lasting immunity.
| Item Type: | Paper |
|---|---|
| Subjects: | diseases & disorders > cancer diseases & disorders diseases & disorders > cancer > cancer types > pancreatic cancer diseases & disorders > cancer > cancer types |
| CSHL Authors: | |
| Communities: | CSHL labs > Egeblad lab CSHL labs > Westcott lab |
| SWORD Depositor: | CSHL Elements |
| Depositing User: | CSHL Elements |
| Date: | 13 May 2025 |
| Date Deposited: | 16 May 2025 12:35 |
| Last Modified: | 16 May 2025 12:35 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/41876 |
Actions (login required)
 |
Administrator's edit/view item |